Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections

+ Market Ready CBD Derma Cosmetic Brand And Patent-Pending CBD Pain Relief Brand

Sponsored
Innocan Pharma Profile

Innocann large

https://innocanpharma.com/

InnoCan – Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections 

InnoCan Pharma Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids

WHY INNOCAN?

InnoCan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

PHARMACEUTICAL - THE GUIDED MISSILE

  • Revolutionary Technology Targeting Lungs Infected  With Coronavirus or other viral infections 
    • Done By Combining CBD with Stem Cell Particles (Exosomes)
    • Research & Licensing Agreement with Tel Aviv University
  • Developing CLX, The ICBM Ballistic Missile Of Coronavirus Lung Infections
  • Separate breakthrough delivery and control release technology that enables the injection of CBD.

CONSUMER RETAIL – DERMA COSMETICS 

  • A Premium Derma Cosmetics Brand
  • Containing Highly Concentrated Ingredients Formulated with CBD
  • Manufacturing & Supply Agreements - Europe and United States
  • Manufacturing Has Commenced For 9 Products As Of Q2 2020
  • Distribution Agreements - United Kingdom and Ireland
  • Completed Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF

  • Patent-Pending CBD Pain Relief Brand
  • Versions Include Spray, Roll-On and Cream
  • Relief & Go Spray – First Product Being Manufactured
    • FDA Technical Validation
    • FDA Approval To Commence Marketing In The United States
  •   Manufacturing Commencement
    • New Jersey (United States Market)
    • Portugal (Asia and Europe Markets)
  • Sales Commenced In H2 2020 during September

     SUPERIOR MANAGEMENT TEAM

  • The InnoCan Leadership Group Is Incomparable In The Small Cap World
  • Comprised Of Leading Israeli Pharmaceutical Executives
  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
  • Together they have built a formidable team at InnoCan

SEEING IS BELIEVING

INNOCAN PHARMACEUTICAL – DEVELOPING THE CLX GUIDED MISSILE TO DEFEAT CORONAVIRUS LUNG INFECTIONS

WHAT IS CLX? THE COMBINATION OF CBD AND EXOSOMES

ICBMs (Intercontinental Ballistic Missiles) were developed to deliver precision strikes against military targets.

CLX is the ballistic missile of the pharmaceutical world, being developed by InnoCan to deliver precisions strikes against lung cells infected by Coronavirus.

CLX contains two critical components:

1.  Exosomes - Particles derived from stem cells which have demonstrated an ability to target damaged cell tissue, as well as, assist in their repair.

2.  CBD - A known anti-inflammatory agent

InnoCan technology loads Exosomes with CBD, a known anti-inflammatory agent

Combining the cell healing properties of Exosomes with the anti-inflammatory properties of CBD creates a guided missile to infected lungs.

CLX IS A BREAKTHROUGH INNOVATION USING CBD TO TARGET CORONAVIRUS INFECTED LUNG CELLS

InnoCan is primarily focusing on its breakthrough innovation targeting COVID-19, a global threat, which in many cases affects the lungs.  To do so, InnoCan has created a licensing agreement with Tel Aviv University.

Together, InnoCan and Tel Aviv University are developing CLX, a new, revolutionary Cell Therapy technology to target Coronavirus infected lung cells and other Central Nervous System diseases.

CLX has the potential to combine anti-inflammatory properties AND assist in the recovery of infected lung cells.  It is expected to be administered by inhalation.

CLX will be tested on patients whose lungs have been infected by Coronavirus.

CLX can potentially be used for the treatment of other types of lung inflammations that have resulted from viral infections such as SARS and MERS.

The market opportunities for Exosome-Based technologies are proven and big.  

INNO-pic-1

INJECTABLE CBD DELIVERY SYSTEM

inno4

INNOCAN’S COMMERCIAL RETAIL PRODUCT LINES

  • Shir Beauty & Science - Premium CBD Derma Cosmetic Brand
  • Relief & Go - Breakthrough Patent-Pending CBD Pain Relief Brand.

Shir Beauty & Science 

Powered by Science, Inspired by Nature

SHIR Beauty & science skincare brand combines the benefits of CBD with the most effective ingredients in innovative formulas to deliver visible results

  • Signed two manufacturing & supply agreements with European and USA facilities
  • Manufacturing underway with nine products available soon
  • Entered into a manufacturing and distribution agreement  with Endless Sky Incorporated, a Canadian large scale Cannabis extractor based in Calgary, Alberta.
    • ESI will serve as the exclusive distributor of Innocan's CBD products in Canada under a license granted by Innocan.
    • ESI will manufacture Innocan's CBD products at ESI's Health Canada licensed facility in Redvers, Saskatchewan.
    • ESI's manufacturing and distribution rights consist of the Relief and Go CBD Spray and Cream and the SHIR Eye Serum, Face Cream and Night Cream.
    • According to the agreement, ESI shall pay Innocan Israel a cash license fee per Product as well as royalties based on net sales of the Products by ESI.
  • Signed distribution agreement for UK and Ireland

MEET THE PRODUCT LINE

CBD+

Premium Collection created with a triple dose of pure 300mg CBD and an Anti-aging complex designed to retain the skins elasticity, strength, and firmness for natural radiance.

SHIR-1

CBD MUST

Formulated with highly effective pure 100mg CBD and effective ingredients designed to nourish and hydrate the skin for a natural glow.

CBD-Must-1

CBD-Must-2

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6922/58590_ec5d52aca4644ab8_002.jpg

 RELIEF & GO

  • A breakthrough patent-pending CBD pain relief brand.
  • NOTE: Charlotte’s Web recently purchased Abacus Health Products with its products similar to our R&G relief.

InnoCan Pharma (CSE:INNO) Share Price | RNS News, Quotes, & Charts | |

The company received notice from the FDA that Relief & Go Pain Relief spray product has successfully received technical validation and approval to commence marketing in the USA.

RandG

Innocan's pain relief formulation contains a combination of Magnesium oil, Methyl salicylate, Menthol and CBD. The Relief & GO Pain Relief spray is designed to target pain-related muscle and provide relief for joint pain. The unique formulation is administered with a simple dose of spray, roll-on or lotion. 

  • Products are now being produced by two manufacturers: one in New Jersey for the US market, and one in Portugal for Asia and Europe.
  • The first product being manufactured is The Patent Pending Relief & Go CBD Spray
  • Sales will start in the second half of 2020

https://orders.newsfilecorp.com/files/6922/57340_4dab2b3a54d19926_002full.jpg

 INNO-3

 

Last changed at 25-Sep-2020 03:01PM by AGORACOM